This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| metastatic melanoma | |
|---|---|
| Name | Metastatic melanoma |
| Caption | Advanced cutaneous melanoma with metastatic spread |
| Synonyms | Stage IV melanoma |
| Specialty | Oncology, Dermatology |
| Symptoms | Variable cutaneous lesions, systemic symptoms |
| Complications | Organ failure, cachexia, paraneoplastic syndromes |
| Onset | Variable |
| Duration | Chronic, progressive without control |
| Causes | Malignant transformation of melanocyte |
| Diagnosis | Histopathology, imaging, molecular testing |
| Treatment | Surgery, immunotherapy, targeted therapy, radiation, palliative care |
metastatic melanoma is the advanced stage of malignant melanoma characterized by dissemination of malignant melanocyte-derived tumor cells to regional lymph nodes and distant organs. It represents a clinically heterogeneous condition managed by multidisciplinary teams including specialists from Oncology, Dermatology, Surgery, Radiation Oncology, and Pathology. Management options and outcomes have been transformed by advances linked to discoveries celebrated by awards such as the Nobel Prize in Physiology or Medicine.
Patients may present with progression of a primary pigmented lesion or new lesions and systemic complaints. Local signs often include enlarging pigmented nodules and ulceration, while regional spread produces palpable adenopathy in fields drained by the primary site, prompting referral to centers like Memorial Sloan Kettering Cancer Center or Mayo Clinic. Distant metastases cause organ-specific syndromes: pulmonary involvement yields dyspnea and hemoptysis, hepatic disease causes hepatomegaly and cholestatic features, cerebral metastases produce headaches and focal deficits prompting neuroimaging at institutions such as Massachusetts General Hospital or Johns Hopkins Hospital. Constitutional symptoms—weight loss, anorexia, cachexia—lead to palliative care coordination with programs like St. Christopher's Hospice.
Melanoma arises from malignant transformation of melanocytes driven by mutational events in oncogenes and tumor suppressors, including alterations in BRAF, NRAS, and CDKN2A. Tumor cells invade locally through changes in adhesion molecules and matrix metalloproteinases, enter lymphatic channels to produce nodal metastases, and disseminate hematogenously to lungs, liver, brain, and bone. Molecular pathways such as the MAPK pathway and alterations in PTEN and PI3K/AKT pathway underpin therapy resistance observed in cohorts treated at centers including Dana-Farber Cancer Institute and University of Texas MD Anderson Cancer Center. Tumor microenvironment interactions with immune checkpoints like PD-1 and CTLA-4 determine response to checkpoint inhibitors developed by companies and research programs linked to investigators honored by prizes including the Lasker Award.
Diagnostic confirmation requires histopathologic evaluation of biopsy specimens with immunohistochemistry for markers including S100, HMB-45, and SOX10, performed in pathology departments such as those at Cleveland Clinic or UCLA Medical Center. Staging and detection of metastatic disease employ cross-sectional imaging—CT and MRI—often coordinated through radiology services at Royal Marsden Hospital or Brigham and Women's Hospital. PET-CT is frequently used for whole-body assessment; cerebral metastases are best characterized by MRI with contrast. Molecular testing for actionable mutations (e.g., BRAF V600E) and assessment of PD-L1 expression guides therapy selection in trials conducted at National Cancer Institute and cooperative groups like European Organisation for Research and Treatment of Cancer.
Staging follows the tumor-node-metastasis (TNM) framework developed and maintained by organizations including the American Joint Committee on Cancer and the Union for International Cancer Control. Stage IV designates distant metastasis and is subclassified by factors such as site of metastasis, serum lactate dehydrogenase (LDH), and number of involved organs; these criteria inform prognostic models utilized by registries like the Surveillance, Epidemiology, and End Results Program. Clinical trial stratification from cooperative groups such as EORTC relies on these staging definitions.
Management is multimodal and individualized. Surgical resection of isolated metastases can be curative in select patients and is performed at tertiary centers like Memorial Sloan Kettering Cancer Center. Systemic therapy options include immune checkpoint inhibitors (anti–PD-1 agents such as pembrolizumab and nivolumab; anti–CTLA-4 agent ipilimumab) and targeted therapies for BRAF-mutant tumors (BRAF inhibitors plus MEK inhibitors), developed and validated in trials conducted by institutions including Dana-Farber Cancer Institute and pharmaceutical consortia. Radiation therapy is used for palliation and for brain metastases with stereotactic radiosurgery programs at centers such as MD Anderson Cancer Center. Enrollment in clinical trials organized by groups like the National Comprehensive Cancer Network and EORTC is encouraged for refractory disease. Supportive and palliative care, often coordinated with organizations like Macmillan Cancer Support, address symptom control and quality of life.
Prognosis varies widely: patients with limited resectable disease may achieve long-term survival after metastasectomy, whereas widespread visceral or cerebral involvement confers a poorer outlook. Survival metrics reported by population registries including SEER and institution-specific series from Royal Marsden Hospital and Memorial Sloan Kettering Cancer Center show improved median overall survival since the introduction of checkpoint inhibitors and targeted therapies, with durable responses observed in a subset of patients treated on trials supported by the National Institutes of Health.
Incidence of melanoma has risen in populations monitored by surveillance programs like SEER and public health agencies such as Centers for Disease Control and Prevention. Major epidemiologic risk factors include ultraviolet radiation exposure patterns associated with geographic regions like Australia and New Zealand, phenotypic traits linked to genetic studies involving families investigated at institutions like University of Cambridge and University of Oxford, and germline predisposition involving CDKN2A mutations identified in consortia including the International Melanoma Genetics Consortium. Occupational and recreational exposures, alongside demographic variables tracked by agencies such as World Health Organization, influence risk and prevention strategies driven by public health campaigns in countries including United States and United Kingdom.